Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

GESTALT Barcoding and Single-cell Transcriptomics of Tumor Cell Evolution in Personalized Tumor Models

Award Number: R33CA236687
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/11/2019
PERIOD OF PERFORMANCE END DATE: 03/31/2022

Group Awards By:

View Award Description

GESTALT Barcoding and Single-cell Transcriptomics of Tumor Cell Evolution in Personalized Tumor Models - PROJECT SUMMARY / ABSTRACT Identification of somatic mutations in diverse tumor types has grown exponentially with the development of next-generation sequencing technologies. However, there is a pressing need to validate putative cancer driver genes and separate them from coincidental “passenger” mutations. Further, it is becoming clear that many cancers are highly heterogeneous in terms of the polyclonality of somatic genotypes—often expressing multiple driver mutations simultaneously or in different subpopulations. Moreover, standard of care treatment often induces selective pressures resulting in significant alterations in recurrent populations. We are only in the beginning stages of validating driver genes in many tumor types and are even further behind in studying mechanisms of evolution and recurrence in these systems. The central theme of this grant application is to generate a toolset marrying patient-derived, “personalized” somatic mutation signatures with genome editing of synthetic target arrays for lineage tracing (GESTALT) for the elucidation of the transcriptomic mechanisms leading to tumor diversity. Specifically, we will generate a pipeline for isolating single-cell transcriptomes and GESTALT barcodes to classify and lineage map large numbers of tumor populations over time, including after the selective pressures of standard of care treatment. Over the past several years, we have pioneered an electroporation-based somatic mutation method for rapid, non-invasive, somatic transgenesis for high throughput validation of tumor driver genes using mosaic analysis with dual recombinase-mediated cassette exchange (MADR). We will employ novel in vivo MADR models of glioma as a test case for the utilization of this system for later use with diverse tumor types. The overall objective of the proposal is to perform advanced development of this combined MADR-GESTALT approach to allow for generalized use in diverse tumor contexts and, therefore, demonstrate the potential of this technology to transform cancer research. We propose to carry out this work in three parts. The focus of Specific Aim 1 is to optimize the combined MADR-GESTALT system for generating tumor cell classification by transcriptome and lineage maps. The main goal of Specific Aim 2 is to rigorously validate MADR-GESTALT inducible elements in the context of clinical standard of care treatment. Finally, to prepare for widespread dissemination of these tools, in Specific Aim 3 we will generate and validate knock-in mice with GESTALT elements for tissues not amenable to electroporation. Successful completion of these experiments will create the foundation for a long-lived, cornerstone toolset for understanding both basic and pathologic mechanisms of the disease as well as providing definitive, genetic insights into the cellular and transcriptomic mechanisms of progression and recurrence in a diverse array of cancers.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = -$2,790 )
2022	2021	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cancer Biology Research	000	3	9/1/2022	NON-COMPETING CONTINUATION	-$2,790
														Subtotal = -$2,790

Issue Date FY: 2021 ( Subtotal = $413,102 )
2021	2021	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Cancer Biology Research	000	3	3/11/2021	NON-COMPETING CONTINUATION	$413,102
														Subtotal = $413,102

Issue Date FY: 2020 ( Subtotal = $413,102 )
2020	2020	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Cancer Biology Research	000	2	3/9/2020	NON-COMPETING CONTINUATION	$413,102
														Subtotal = $413,102

Issue Date FY: 2019 ( Subtotal = $413,100 )
2019	2019	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Cancer Biology Research	000	1	4/11/2019	NEW	$413,100
														Subtotal = $413,100

Grand Total All Awards = $1,236,514

Top

All Categories

About

Search

Reports

Data Submission

Award Information

GESTALT Barcoding and Single-cell Transcriptomics of Tumor Cell Evolution in Personalized Tumor Models

Award Number: R33CA236687

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/11/2019

PERIOD OF PERFORMANCE END DATE: 03/31/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer